The University of Chicago Header Logo

Connection

Mary Dolan to Neoplasms

Back to Details
This is a "connection" page, showing publications Mary Dolan has written about Neoplasms.
Mary Dolan
Connection Strength
2.688
Neoplasms
  1. Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer. Cancer Med. 2023 02; 12(3):2999-3012.
    View in: PubMed
    Score: 0.257
  2. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021 Nov 01; 127(21):4091-4102.
    View in: PubMed
    Score: 0.237
  3. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
    View in: PubMed
    Score: 0.224
  4. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
    View in: PubMed
    Score: 0.196
  5. Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:775-786.
    View in: PubMed
    Score: 0.190
  6. Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019.
    View in: PubMed
    Score: 0.177
  7. Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res. 2012 May 15; 18(10):2791-800.
    View in: PubMed
    Score: 0.125
  8. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
    View in: PubMed
    Score: 0.123
  9. The use of genomic information to optimize cancer chemotherapy. Semin Oncol. 2011 Apr; 38(2):186-95.
    View in: PubMed
    Score: 0.116
  10. The emerging role of microRNAs in drug responses. Curr Opin Mol Ther. 2010 Dec; 12(6):695-702.
    View in: PubMed
    Score: 0.113
  11. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14.
    View in: PubMed
    Score: 0.103
  12. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8.
    View in: PubMed
    Score: 0.095
  13. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007 Sep; 8(9):1159-68.
    View in: PubMed
    Score: 0.091
  14. Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors. Sci Rep. 2024 11 14; 14(1):27952.
    View in: PubMed
    Score: 0.075
  15. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.064
  16. Changes in the Vaginal Microbiome and Associated Toxicities Following Radiation Therapy for Gynecologic Cancers. Front Cell Infect Microbiol. 2021; 11:680038.
    View in: PubMed
    Score: 0.060
  17. Comparisons of Depression, Sexual Function, and Quality of Life Between Women With Gynecological Cancers and Race-Matched Healthy Controls. Cancer Nurs. 2021 Mar-Apr 01; 44(2):116-124.
    View in: PubMed
    Score: 0.058
  18. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
    View in: PubMed
    Score: 0.050
  19. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018 10; 2(10):744-754.
    View in: PubMed
    Score: 0.049
  20. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
    View in: PubMed
    Score: 0.048
  21. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
    View in: PubMed
    Score: 0.044
  22. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
    View in: PubMed
    Score: 0.037
  23. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
    View in: PubMed
    Score: 0.033
  24. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
    View in: PubMed
    Score: 0.029
  25. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4.
    View in: PubMed
    Score: 0.027
  26. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
    View in: PubMed
    Score: 0.025
  27. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
    View in: PubMed
    Score: 0.014
  28. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.012
  29. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
    View in: PubMed
    Score: 0.009
  30. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.005
  31. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.